{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T17:04:05Z","timestamp":1766941445177,"version":"3.30.2"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Die kardioonkologische Leitlinie, ver\u00f6ffentlicht in Zusammenarbeit mit der EHA (Europ\u00e4ische Gesellschaft f\u00fcr H\u00e4matologie), der ESTRO (Europ\u00e4ische Gesellschaft f\u00fcr therapeutische Radiologie und Onkologie) und der ESC (Europ\u00e4ische Gesellschaft f\u00fcr Kardiologie), bietet 272 Empfehlungen zur Risikostratifizierung vor Therapiebeginn, zum Monitoring w\u00e4hrend der Therapie und zur Behandlung therapieassoziierter kardiovaskul\u00e4rer Nebenwirkungen.<\/jats:p><jats:p>\n            Risikostratifizierung Bei allen onkologischen Patienten soll vor Beginn einer neuen Systemtherapie eine Risiko-Einordnung durchgef\u00fchrt werden. Anhand dieser staffelt sich die Empfehlung zur weiteren kardiologischen Betreuung w\u00e4hrend der Chemotherapie.<\/jats:p><jats:p>\n            Individualisierte Strategien In einzelnen Bereichen, bspw. bei Immun-Checkpoint-Inhibitoren oder zur m\u00f6glichen protektiven Wirkung von Statinen bei Anthrazyklin-Therapie, gibt es neuere Daten, die noch nicht in der Guideline ber\u00fccksichtigt werden konnten.<\/jats:p><jats:p>\n            Protektion und Behandlung toxischer Nebenwirkungen Generell sollte bei moderater oder schwerer Kardiotoxizit\u00e4t eine Unterbrechung oder ein Abbruch der Therapie erwogen werden. Gegebenenfalls kann die Hinzunahme eines ACE-Blockers, Angiotensin-Rezeptor-Blockers oder eines Betablockers erwogen werden.<\/jats:p><jats:p>\n            Echokardiografische Parameter Die Leitlinie empfiehlt die Parameter LVEF und GLS, doch muss eine Therapieentscheidung, basierend auf dem GLS allein, nach aktueller Datenlage abgelehnt werden.<\/jats:p><jats:p>\n            Praktische Umsetzung Die Leitlinie betont die Bedeutung interdisziplin\u00e4rer Betreuung zwischen Onkologen und Kardiologen.<\/jats:p><jats:p>\n            Wie geht es weiter in der Kardioonkologie? Eine weitere Individualisierung der kardioonkologischen Therapie ist w\u00fcnschenswert und sollte das Ziel sein. KI-gest\u00fctzte Systeme sollten weiterentwickelt und etabliert werden.<\/jats:p>","DOI":"10.1055\/a-2104-6363","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T22:43:13Z","timestamp":1716504193000},"page":"719-723","source":"Crossref","is-referenced-by-count":2,"title":["Update zur ESC-Leitlinie Kardioonkologie"],"prefix":"10.1055","volume":"149","author":[{"given":"Sebastian Welf","family":"Romann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III - Kardiologie, Angiologie und Pneumologie, Universit\u00e4tsKlinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III - Kardiologie, Angiologie und Pneumologie, Universit\u00e4tsKlinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III - Kardiologie, Angiologie und Pneumologie, Universit\u00e4tsKlinikum Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00392-022-02001-6","article-title":"Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients-a large monocenter cohort study","volume":"112","author":"D Finke","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ehf2.14587","article-title":"Cardiological parameters predict mortality and cardiotoxicity in oncological patients","volume":"11","author":"SW Romann","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"41","key":"ref3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"AR Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"06","key":"ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis","volume":"148","author":"LH Lehmann","year":"2023","journal-title":"Circulation"},{"issue":"05","key":"ref5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis","volume":"13","author":"JE Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"09","key":"ref6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"S Martel","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"E de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia","volume":"122","author":"C Iliescu","year":"2018","journal-title":"Am J Cardiol"},{"issue":"05","key":"ref9","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)","volume":"87","author":"CA Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"issue":"36","key":"ref10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"06","key":"ref11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial","volume":"330","author":"TG Neilan","year":"2023","journal-title":"JAMA"},{"issue":"06","key":"ref12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"P Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.amjcard.2023.08.123","article-title":"Statins for Primary Prevention of Anthracycline Chemotherapy-Related Cardiac Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"206","author":"S Agarwal","year":"2023","journal-title":"Am J Cardiol"},{"issue":"03","key":"ref14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial","volume":"16","author":"T Negishi","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"04","key":"ref15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00392-018-1202-x","article-title":"Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome","volume":"107","author":"LM Tilemann","year":"2018","journal-title":"Clin Res Cardiol"},{"issue":"01","key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40959-023-00179-w","article-title":"Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology","volume":"9","author":"SA Brown","year":"2023","journal-title":"Cardiooncology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3102.","article-title":"European Society of Cardiology Core Curriculum for cardio-oncology","author":"T Lopez-Fernandez","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"ref18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: rationale, organization, and implementation","volume":"40","author":"P Lancellotti","year":"2019","journal-title":"Eur Heart J"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2104-6363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:32:53Z","timestamp":1734352373000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2104-6363"}},"subtitle":["Neue Ans\u00e4tze zur Bew\u00e4ltigung kardiovaskul\u00e4rer Risiken bei Krebspatienten"],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2104-6363","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}